HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideLeo Luznik, Ephraim J. Fuchs, Paul V. O’Donnell et al.|Biology of Blood and Marrow Transplantation|2008Cited by 1.9k
Neonatal Tolerance Revisited: Turning on Newborn T Cells with Dendritic CellsJ P Ridge, Polly Matzinger, Ephraim J. Fuchs|Science|1996Cited by 763
B Cells Turn Off Virgin But Not Memory T CellsEphraim J. Fuchs, Polly Matzinger|Science|1992Cited by 570
Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant CyclophosphamideAsad Bashey, Mary Eapen, Mei-Jie Zhang et al.|Journal of Clinical Oncology|2017Cited by 325
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R. McCurdy, Yvette L. Kasamon, Jennifer A. Kanakry et al.|Blood|2015Cited by 299